(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.77%.
Inovio Pharmaceuticals's earnings in 2024 is -$121,640,471.On average, 4 Wall Street analysts forecast INO's earnings for 2024 to be -$120,409,293, with the lowest INO earnings forecast at -$129,042,412, and the highest INO earnings forecast at -$113,463,851. On average, 4 Wall Street analysts forecast INO's earnings for 2025 to be -$95,483,596, with the lowest INO earnings forecast at -$120,214,561, and the highest INO earnings forecast at -$75,556,020.
In 2026, INO is forecast to generate $18,694,273 in earnings, with the lowest earnings forecast at -$45,956,754 and the highest earnings forecast at $83,345,300.